A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms

Pharmacogenetics

Volumn 12, Issue 2, 2002, Pages 133-144

  Mattison, Lori K ^a   Johnson, Martin R ^a   Diasio, Robert B ^a  

^a University of Alabama School of Medicine   (United States)

Author keywords

5 fluorouracil; Dihydropyrimidine dehydrogenase; Dihydropyrimidine dehydrogenase deficiency; Pharmacogenetic; Pharmacogenomic; Species comparison

Indexed keywords

COMPLEMENTARY DNA; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; IRON SULFUR PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; URACIL;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ARTHROPOD; ARTICLE; CAENORHABDITIS ELEGANS; CHORDATA; CONTROLLED STUDY; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DISEASE ASSOCIATION; DROSOPHILA MELANOGASTER; DRUG BINDING SITE; DRUG INDUCED DISEASE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME POLYMORPHISM; ENZYME STRUCTURE; GENE LOCUS; GENE MUTATION; HUMAN; INVERTEBRATE; MAMMAL; NEMATODE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; RNA TRANSLATION; SEQUENCE HOMOLOGY; SPECIES COMPARISON;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CAENORHABDITIS ELEGANS; CATTLE; CLONING, MOLECULAR; DIHYDROURACIL DEHYDROGENASE (NADP); DNA, COMPLEMENTARY; DROSOPHILA; FLAVIN MONONUCLEOTIDE; FLAVIN-ADENINE DINUCLEOTIDE; FLUOROURACIL; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NADP; OXIDOREDUCTASES; POLYMORPHISM, GENETIC; RATS; SEQUENCE HOMOLOGY, AMINO ACID; SWINE; URACIL;

ARTHROPODA; CAENORHABDITIS; CAENORHABDITIS ELEGANS; CHORDATA; DROSOPHILA MELANOGASTER; INVERTEBRATA; MAMMALIA; MELANOGASTER; NEMATODA;

EID: 0036219855     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200203000-00007     Document Type: Article

References (43)

1. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil
2. Fluoropyrimidines
3. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
4. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy
5. Apoptosis by antitumor agents and other factors in relation to cell cycle checkpoints
6. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs
7. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase
8. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity
9. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil
10. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil
11. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
12. Purification and characterization of dihydropyrimidine dehydrogenase from human liver
13. Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization
14. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria
15. Structural organization of the human dihydropyrimidine dehydrogenase gene
16. Porcine recombinant dihydropyrimidine dehydrogenase: Comparison of the spectroscopic and catalytic properties of the wild-type and C671A mutant enzymes
17. Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil
18. Nomenclature for human DPYD alleles
19. Known variant DPYD alleles do not explain DPD deficiency in cancer patients
20. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
21. Sequence alignment and database searching
22. cDNA cloning of bovine liver dihydropyrimidine dehydrogenase
23. Cloning of rat dihydropyrimidine dehydrogenase and correlation of its mRNA increase in the rat liver with age
24. Purification and properties of dihydrothymine dehydrogenase from rat liver
25. Purification and characterization of dihydropyrimidine dehydrogenase from pig liver
26. Inactivation of dihydropyrimidine dehydrogenase by 5-iodouracil
27. Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties
28. Rubredoxin reductase of Pseudomonas oleovorans. Structural relationship to other flavoprotein oxidoreductases based on one NAD and two FAD fingerprints
29. On the iron-sulfur clusters in the complex redox enzyme dihydropyrimidine dehydrogenase
30. A homologue of a nuclear-coded iron-sulfur protein subunit of bovine mitochondrial complex I is encoded in chloroplast genomes
31. Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene
32. Dihydropyrimidine dehydrogenase deficiency: A novel mutation and expression of missense mutations in E. coli
33. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects
34. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
35. Characterization of the human dihydropyrimidine dehydrogenase gene
36. Dihydropyrimidine dehydrogenase (DPD) deficiency: Identification and expression of missense mutations C29R, R886H and R235W
37. Molecurar cloning and characterization of the human dihydropyrimidine dehydrogenase promoter
38. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
39. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy
40. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity
41. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction
42. Cell cycle-coupled variation in topoisomerase IIalpha mRNA is regulated by the 3′-untranslated region. Possible role of redox-sensitive protein binding in mRNA accumulation
43. NetOglyc: Prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility